This report from Syneos and UserCue presents findings from a research project that interviewed 15 US health insurance executives. The study explores forthcoming challenges and uncertainties within health insurance coverage and drug pricing, particularly focusing on pharmaceutical manufacturers' need to adapt. Key issues discussed include the Inflation Reduction Act, specialty drug spending, cell and gene therapy costs, biosimilar adoption, and employer-customer demands. The report also examines current strengths and areas for improvement for payers, emphasizing access to branded pharmaceuticals and specific considerations for rare diseases like ATTR Cardiomyopathy. For more information contact Aaron Davis at aaron.davis@syneoshealth.com.